Patents by Inventor Harald Engelhardt

Harald Engelhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230374021
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 23, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230126204
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the R groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230131720
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
    Patent number: 11608343
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Birgit Wilding, Dietrich Boese, Harald Engelhardt, Julian Fuchs, Ralph Neumueller, Mark Petronczki, Dirk Scharn, Matthias Treu
  • NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20220380382
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 1, 2022
    Inventors: Harald ENGELHARDT, Dietrich BOESE
  • SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20220133734
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventors: Harald ENGELHARDT, Mark PETRONCZKI, Juergen RAMHARTER, Ulrich REISER, Heinz STADTMUELLER, Dirk SCHARN, Tobias WUNBERG
  • [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
    Patent number: 11261184
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: March 1, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Heribert Arnhof, Sebastian Carotta, Marco Hofmann, Marc Kerenyi, Dirk Scharn
  • Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
    Patent number: 11213520
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 4, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Heribert Arnhof, Sebastian Carotta, Marco Hans Hofmann, Marc Kerenyi, Dirk Scharn
  • Benzimidazole compounds and derivatives as EGFR inhibitors
    Patent number: 11174245
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dietrich Boese, Georg Dahmann, Harald Engelhardt, Mark Petronczki, Dirk Scharn
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20210332054
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 28, 2021
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Triazolopyrazine
    Patent number: 11077107
    Abstract: Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: August 3, 2021
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20200377476
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Dietrich BOESE, Georg DAHMANN, Harald ENGELHARDT, Mark PETRONCZKI, Dirk SCHARN
  • NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS
    Publication number: 20200291020
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 17, 2020
    Inventors: Harald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco HOFMANN, Marc KERENYI, Dirk SCHARN
  • NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS
    Publication number: 20190290637
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventors: Harald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco Hans HOFMANN, Marc KERENYI, Dirk SCHARN
  • TRIAZOLOPYRAZINE
    Publication number: 20190240219
    Abstract: Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 8, 2019
    Inventors: Harald ENGELHARDT, Davide GIANNI, Christian SMETHURST
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors
    Patent number: 10328074
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Triazolopyrazine
    Patent number: 9428513
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Benzimidazole derivatives
    Patent number: 9428515
    Abstract: The present invention encompasses compounds of the general formula I wherein the groups A, R1 to R2 and X have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Triazolopyridazine
    Patent number: 9422290
    Abstract: Disclosed are compounds of general formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: August 23, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Dirk Kessler, Ulrich Reiser, Christian Smethurst, Andreas Steffen
  • SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS
    Publication number: 20160129001
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Application
    Filed: January 14, 2016
    Publication date: May 12, 2016
    Inventors: Harald ENGELHARDT, Davide GIANNI, Christian SMETHURST